New episode of The Good GP podcast available: COVID-19 vaccination in children
A new episode of The Good GP podcast is now available. In this COVID-19 vaccination episode, The Good GP interviews Dr Angie Berkhout, paediatric infectious diseases physician at the Royal Children's Hospital, on the COVID-19 vaccination rollout in children aged 5-11.
The interview covers the Pfizer vaccination available for children, schedules, efficacy, contraindications and precautions. They also bust some common myths regarding the COVID-19 vaccine in children.
To listen to the podcast, please click on the link below:
The Good GP podcast episode available: COVID-19 vaccination in children
WHO: 2021 has been tumultuous but we know how to end the pandemic and promote health for all in 2022
In 2021, the global health system faced significant challenges perpetuated by the ongoing COVID-19 pandemic. Proving that when health is at risk, everything is at risk. However, there have still been medical breakthroughs and progress including new COVID-19 treatments, the introduction of the world’s first malaria vaccine and the near eradication of polio disease.
The year 2022 brings a hopeful glimpse to end the COVID-19 pandemic, through countries working together, pushing for greater vaccine equity to reach a 70% global vaccination rate.
In this article, the WHO reflects on the challenges and triumphs of the global health system throughout 2021 and outlines some positive opportunities for the coming new year.
पूरा लेख पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें।
2021 has been tumultuous but we know how to end the pandemic and promote health for all in 2022
CDC: COVID-19 Vaccine Safety in Children Aged 5-11 Years November 3 – December 19 2021
Following the administration of approximately 8 million Pfizer COVID-19 vaccine doses in children between the ages of 5 to 11 years, local and systemic reactions were closely monitored and assessed. The incoming data was reported to VAERS and v-safe, the national passive vaccine safety surveillance system, jointly managed by the CDC and FDA. During the span of 3 November to 19 December, 4,249 reports were submitted, of which 97% were for nonserious adverse events.
For the most recent clinical data regarding the safety and efficacy of the Pfizer COVID-19 vaccine in children aged 5 to 11 years, read the full VAERS report.
COVID-19 Vaccine Safety in Children Aged 5-11 Years November 3 – December 19 2021
ATAGI Statement on the Omicron variant and the timing of COVID-19 booster vaccination
In response to the emergence of the Omicron variant of COVID-19 disease and it's community transmission within Australia, the Australian Technical Advisory Group on Immunisation (ATAGI) has updated recommendations for the timing of COVID-19 vaccine booster doses.
These updated recommendations are based on strong evidence indicating that booster doses are likely to increase protection against infection with the Omicron variant, as well as reassuring international data on the safety of administering early booster doses.
These recommendations include:
- all adults (≥ 18 years) should receive a single booster dose of COVID-19 vaccine
- booster doses can be administered as early as 3 months following the completion of a primary course
- timely booster doses for pregnant women is recommended
- immunocompromised individuals who have received a 3-dose primary course should also receive a booster dose 3 months after the date of their 3rd dose
- Comirnaty (Pfizer) and Spikevax (Moderna) are the preferred brands for booster doses. Vaxzevria (AstraZeneca) can be used as a booster dose for individuals with a contraindication to receiving Comirnaty or Spikevax.
ATAGI also encourages anyone aged 12 years or older who is unvaccinated to receive COVID-19 vaccination as soon as possible.
To read the latest update in full please refer to
ATAGI Statement on the Omicron variant and the timing of COVID-19 booster vaccination
European Commission authorises fifth safe and effective vaccine against COVID-19
Nuvaxovid, a COVID-19 vaccine developed by Novavax, has become the fifth COVID-19 vaccine authorised for use in the European Union (EU). Following rigorous safety, efficacy and quality testing by the European Medicines Agency (EMA), the European Commissions has granted a conditional marketing authorization (CMA) of the vaccine for its perceived benefits in providing protection against severe COVID-19 disease.
पूरा बयान पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
European Commission authorises fifth safe and effective vaccine against COVID-19
Pfizer and BioNTech provide update on ongoing studies of COVID-19 vaccine
Following a routine review examining the safety and efficacy of the Pfizer-BioNTech by the external Independent Data Monitoring Committee (DMC), data has demonstrated that whilst there were no safety concerns, immunogenicity of a two dose primary course consisting of 3µg doses in the 6 to 24 month-old cohort was met with non-inferiority, but not in the 2 - 5 year old group.
The company has also announced that it will resume studies evaluating a third 3µg dose of COVID-19 vaccine in children 6 months to under 5 years of age in order to select the right dose to maximise the risk-benefit profile in this age group.
For further information on this study and its findings, follow the link below:
Pfizer and BioNTech provide update on ongoing studies of COVID-19 vaccine
सिडनी मॉर्निंग हेराल्ड: मॉडर्न COVID-19 वैक्सीन बूस्टर खुराक 'ओमिक्रॉन के खिलाफ सुरक्षात्मक प्रतीत होता है'
प्रयोगशाला परीक्षण के बाद, डेटा से पता चलता है कि स्पाइकवैक्स (मॉडर्न) वैक्सीन के दो-खुराक प्राथमिक पाठ्यक्रम के परिणामस्वरूप ओमिक्रॉन वैरिएंट के खिलाफ एंटीबॉडी को बेअसर करने की कम पीढ़ी हुई, एक बूस्टर खुराक ने एंटीबॉडी को बेअसर करने में 37 गुना वृद्धि प्रदान की।
इन निष्कर्षों पर अधिक जानकारी के लिए नीचे दिए गए लिंक के माध्यम से पूरा लेख देखें:
मॉडर्न COVID-19 वैक्सीन बूस्टर खुराक 'ओमिक्रॉन के खिलाफ सुरक्षात्मक प्रतीत होती है'
Raising Children Network - COVID-19 vaccination and children: 5-11 years
Immunising children against COVID-19 ensures stronger, longer-lasting protection than infection does. To build the best immunity, ATAGI recommends that children aged 5 to 11 years should have a 2 dose primary course of the Pfizer COVID-19 vaccine, 8 weeks apart.
This Raising Children article developed in collaboration with MVEC explores the safety, efficacy and recommendations for immunising children aged 5 to 11 years against COVID-19.
पूरा लेख पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
COVID-19 vaccination and children: 5-11 years
टीकाकरण पर ऑस्ट्रेलियाई तकनीकी सलाहकार समूह (एटीएजीआई) ने कोविड-19 बूस्टर वैक्सीन के रूप में स्पाइकवैक्स (मॉडर्ना) के उपयोग पर सिफारिशें की
टीजीए से हाल ही में अनुमोदन के बाद, प्रतिरक्षण पर ऑस्ट्रेलियाई तकनीकी सलाहकार समूह (ATAGI) सिफारिश की है 18 वर्ष और उससे अधिक आयु के लोगों (गर्भवती महिलाओं सहित) के लिए COVID-19 बूस्टर वैक्सीन के रूप में स्पाइकवैक्स (मॉडर्ना) का उपयोग, जिन्होंने 5 या अधिक महीने पहले COVID-19 वैक्सीन का अपना प्राथमिक कोर्स पूरा कर लिया है। बूस्टर डोज़ प्राथमिक कोर्स के लिए उपयोग की जाने वाली स्पाइकवैक्स वैक्सीन की अनुशंसित डोज़ से आधी है।
ATAGI ने नोट किया कि पात्र जनसंख्या में ऑस्ट्रेलिया में बूस्टर टीके के रूप में उपयोग के लिए मॉडर्न और फाइजर COVID-19 टीके समान रूप से स्वीकार्य हैं।
To read ATAGI's बूस्टर फॉलो के रूप में मॉडर्न COVID-19 वैक्सीन के उपयोग पर पूर्ण विवरण नीचे दिया गया लिंक:
Updated ATAGI advice on the administration of seasonal influenza vaccines in 2021 (December 2021)
The Australian Technical Advisory Group on Immunisation (ATAGI) has released updated advice for influenza vaccination in 2021.
Due to international borders reopening from November 2021, and greater population movement, seasonal influenza virus is expected to emerge and circulate in Australia outside of the usual influenza season.
Influenza vaccination is recommended for anyone aged 6 months and over who has not had an influenza vaccine this year. In particular, it is strongly recommended for those in higher risk groups.
To read the advice in full, please click on the link below:
Updated ATAGI advice on the administration of seasonal influenza vaccines in 2021 (December 2021)